Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
1. A method of preparing a pharmaceutical composition for administration, comprising reconstituting the contents of a sterile container using a pharmaceutically acceptable diluent, wherein the sterile container comprises:
an antibacterial agent in solid form; and
a compound of Formula (I) in solid form having the structure:
or a pharmaceutically acceptable salt thereof, wherein:
Y is a 1-4 atom alkylene or 2-4 atom alkenylene linker, optionally substituted by one or more substituents selected from the group consisting of Cl, F, CN, CF 3 , —R 9 , —OR 9 , —C(═O)NR 9 R 10 , and —C(═O)OR 9 , wherein said alkylene or alkenylene linker is optionally fused to an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl;
R 1 is selected from a group consisting of —C 1-9 alkyl, —C 2-9 alkenyl, —C 2-9 alkynyl, —NR 9 R 10 , —C 1-9 alkylR 11 , —C 2-9 alkenylR 11 , —C 2-9 alkynylR 11 , -carbocyclyl-R 11 , —CH(OH)C 1-9 alkylR 9 , —CH(OH)C 2-9 alkenylR 9 , —CH(OH)C 2-9 alkynylR 9 , —CH(OH)carbocyclyl-R 9 , —C(═O)R 9 , —C(═O)C 1-9 alkylR 9 , —C(═O)C 2-9 alkenylR 9 , —C(═O)C 2-9 alkynylR 9 , —C(═O)C 2-9 carbocyclyl-R 9 , —C(═O)NR 9 R 10 , —N(R 9 )C(═O)R 9 , —N(R 9 )C(═O)NR 9 R 10 , —N(R 9 )C(═O)OR 9 , —N(R 9 )C(═O)C(═NR 10 )R 9 , —N(R 9 )C(═O)C(═CR 9 R 10 )R 9 , —N(R 9 )C(═O)C 1-4 alkylN(R 9 )C(═O)R 9 , —N(R 9 )C(═NR 10 )R 9 , —C(═NR 10 )NR 9 R 10 , —N═C(R 9 )NR 9 R 10 , —N(R 9 )SO 2 R 9 , —N(R 9 )SO 2 NR 9 R 10 , —N═CHR 9 , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, and optionally substituted heterocyclyl;
R 6 is selected from a group consisting of H, —C 1-9 alkyl, —C 2-9 alkenyl, —C 2-9 alkynyl, carbocyclyl, —C 1-9 alkylR 11 , —C 2-9 alkenylR 11 , —C 2-9 alkynylR 11 , -carbocyclyl-R 11 , —C(═O)OR 9 , —C 1-9 alkylCO 2 R 9 , —C 2-9 alkenylCO 2 R 9 , —C 2-9 alkynylCO 2 R 9 , and -carbocyclyl-CO 2 R 9 , or alternatively:
(i) R 6 and an R 7 are taken together with the atoms to which they are attached to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl, or
(ii) R 6 is absent when the carbon to which it is attached is a ring atom in an aryl or heteroaryl ring;
each R 7 is independently selected from a group consisting of H, halo, —C 1-9 alkyl, —C 2-9 alkenyl, —C 2-9 alkynyl, —NR 9 R 10 , —OR 9 , —C 1-9 alkylCO 2 R 9 , —C 2-9 alkenylCO 2 R 9 , —C 2-9 alkynylCO 2 R 9 , and -carbocyclyl-CO 2 R 9 , or independently:
(i) R 6 and an R 7 are taken together with the atoms to which they are attached to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl, or
(ii) R 7 and an R 8 are taken together with the atoms to which they are attached to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl;
each R 8 is independently selected from a group consisting of H, halo, —C 1-9 alkyl, —C 2-9 alkenyl, —C 2-9 alkynyl, —NR 9 R 10 , —OR 9 , —C 1-9 alkylCO 2 R 9 , —C 2-9 alkenylCO 2 R 9 , —C 2-9 alkynylCO 2 R 9 , and -carbocyclyl-CO 2 R 9 , or independently:
(i) an R 7 and an R 8 are taken together with the atoms to which they are attached to form an optionally substituted carbocyclyl or optionally substituted heterocyclyl,
(ii) a geminal R 7 and R 8 together form —C 2-9 alkenylenylCO 2 R 9 , or
(iii) each R 8 attached to a ring atom forming part of an optionally substituted aryl is absent;
each R 9 is independently selected from a group consisting of H, —C 1-9 alkyl, —C 2-9 alkenyl, —C 2-9 alkynyl, carbocyclyl, —C 1-9 alkylR 11 , —C 2-9 alkenylR 11 , —C 2-9 alkynylR 11 , -carbocyclyl-R 11 , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted —(CH 2 ) 0-3 carbocyclyl, and optionally substituted heterocyclyl;
each R 10 is independently selected from a group consisting of H, —C 1-9 alkyl, —OR 9 , —CH(═NH), —C(═O)OR 9 , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, and optionally substituted heterocyclyl;
each R 11 is independently selected from a group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, and optionally substituted heterocyclyl;
X is selected from a group consisting of —CO 2 R 12 and a carboxylic acid isostere;
R 12 is selected from a group consisting of H, —C 1-9 alkyl, —(CH 2 ) 0-3 —R 11 , —C(R 13 ) 2 OC(O)C 1-9 alkyl, —C(R 13 ) 2 OC(O)R 11 , —C(R 13 ) 2 OC(O)OC 1-9 alkyl, and —C(R 13 ) 2 OC(O)OR 11 ;
each R 13 is independently selected from a group consisting of H and —C 1-4 alkyl; and
m is independently zero or an integer from 1 to 2,
wherein each —C 1-9 alkyl, —C 2-9 alkenyl, and —C 2-9 alkynyl is independently optionally substituted.
2. The method of claim 1 , wherein the diluent is selected from the group consisting of a saline solution, a dextrose solution, and a sodium carbonate solution.
3. The method of claim 1 , wherein the antibacterial agent comprises meropenem, and the compound is:
or a pharmaceutically acceptable salt thereof.
4. A method of administration comprising administering the reconstituted solution of claim 1 intravenously to a patient.
5. The method of claim 4 , wherein the antibacterial agent comprises meropenem, and the compound is:
or a pharmaceutically acceptable salt thereof.